陕西康惠制药股份有限公司2025年半年度报告摘要

Core Viewpoint - The company, Kanghui Pharmaceutical, has released its semi-annual report for 2025, emphasizing the importance of reviewing the full report for a comprehensive understanding of its operational results, financial status, and future development plans [1]. Company Overview - Kanghui Pharmaceutical is identified by the stock code 603139 and is based in Shaanxi, China [2]. - The report indicates that all board members attended the board meeting, and the report has not been audited [2]. Financial Data - The company has provided key financial data in the report, although specific figures are not disclosed in the excerpts [2]. - The report includes information on the top 10 shareholders and their holdings, but details are not provided in the excerpts [2]. Important Matters - The company is required to disclose significant changes in its operational situation during the reporting period and any events that may have a substantial impact on its operations [3].